Citations

Clear

2960 citation(s) found for "Kim, P".

NLRP3 Inflammasome Activation and Altered Mitophagy Are Key Pathways in Inclusion Body Myositis
Naddaf, Elie , Nguyen, Thi Kim Oanh , Gao, Huanyao , Hou, Xu , Fiesel, Fabienne C. , Mandrekar, Jay , Kokesh, Eileen, Harmsen, William S. , Fiesel, Fabienne C , Naddaf, Elie , Watzlawik, Jens O. , Hou, Xu , Kokesh, Eileen, Lanza, Ian R. , Springer, Wolfdieter , Trushina, Eugenia

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | December 26, 2024 | Volume: 16 | Issue: 1 | Pages: No page available

10.1002/jcsm.13672 | PMID 39723571 Get It

ABSTRACT Background Inclusion body myositis (IBM) is the most prevalent muscle disease in adults for which no current treatment exists. The pathogenesis of IBM remains poorly defined. In this study, we aimed to explore the interplay between inflammation and mitochondrial dysfunction in IBM. Methods The study population consisted of 38 IBM patients and 22 age‐ and sex‐matched controls without a myopathy. Mean age was 62.9 years (SD = 9) in IBM group and 59.7 (10) in controls. Bulk RNA sequencing, Meso Scale Discovery electrochemiluminescence (ECL), western blotting, histochemistry and immunohistochemistry were performed on frozen muscle samples from the study participants. Results We demonstrated activation of the NLRP3 inflammasome in IBM muscle samples, with the NLRP3 inflammasome being the most upregulated pathway on RNA sequencing, along with increased expression of NLRP3 and ASC proteins in IBM group. NLRP3 RNA levels most strongly correlated with TLR7 (correlation coefficient ρ = 0.91) and complement activation‐related genes, and inversely correlated with several mitochondria‐related genes among others. On muscle histopathology, there was increased NRLP3 immunoreactivity in both inflammatory cells and muscle fibres. Mitophagy is critical for removing damaged mitochondria and preventing the formation of a vicious cycle of mitochondrial dysfunction—NLRP3 inflammasome activation. Herein, we showed altered mitophagy, as witnessed by the elevated levels of p‐S65‐Ubiquitin, a mitophagy marker, in muscle lysates from IBM patients compared to controls (median of 114.3 vs. 81.25 ECL units, p = 0.005). The p‐S65‐Ubiquitin levels were most significantly elevated in IBM males compared to male controls (136 vs. 83.5 ECL units; p = 0.013), whereas IBM females had milder nonsignificant elevation compared to female controls (97.25 vs. 69 ECL units, p = 0.31). On muscle histopathology, p‐S65‐Ubiquitin aggregates accumulated in muscle fibres that were mostly Type 2 and devoid of cytochrome‐c‐oxidase reactivity. NLRP3 RNA levels correlated with p‐S65‐Ubiquitin levels in both sexes (males: ρ = 0.48, females: ρ = 0.54) but with loss of muscle strength, as reflected by the manual motor test score, only in males (males: ρ = 0.62, females: ρ = −0.14). Lastly, we identified sex‐specific molecular pathways in IBM. Females had upregulation of pathways related to response to stress, which could conceivably offset some of the pathomechanisms of IBM, while males had upregulation of pathways related to cell adhesion and migration. Conclusions There is activation of the NLRP3 inflammasome in IBM, along with altered mitophagy, particularly in males, which is of potential therapeutic significance. These findings suggest sex‐specific mechanisms in IBM that warrant further investigation.
Position statement of the World Endoscopy Organization: Role of endoscopy in screening, diagnosis, and treatment of esophageal superficial squamous neoplasiaia
Hassan, Cesare , Goda, Kenichi, Iyer, Prasad G. , Awadhi, Sameer Al , Lehibi, Abed Al , Arantes, Vitor , Burgos, Herbert, Cerisoli, Cecilio L., Dawsey, Sanford, Fleischer, David, Fluxá, Fernando, Inoue, Haruhiro , John, Sneha , Khashab, Mouen A., Kothari, Shivangi , Lee, Yeong Yeh, Ngamruengphong, Saowanee , Sharara, Ala I. , Shimamura, Yuto , Varocha, Mahachai, Villa‐Gomez, Guido, Wang, Kenneth K. , Yip, Hon Chi , Sharma, Prateek , Lee, Yeong Yeh , Chiu, Philip Wai Yan , Emura, Fabian , G Iyer, Prasad, Kim, Gwang Ha , Shimamura, Yuto , Yip, Hon-Chi , Hassan, Cesare , Lee, Yeong Yeh , Antonelli, Giulio , Burgos, Herbert, Dawsey, Sanford, Draganov, Peter V. , González, Nicolás , Kashin, Sergey V. , Khashab, Mouen A. , Lee, Yeong Yeh, Remes Troche, José M , Varocha, Mahachai, Wang, Wen‐Lun

Mayo Clinic

Digestive Endoscopy | December 26, 2024 | Volume: 37 | Issue: 5 | Pages: 470-489

10.1111/den.14967 | PMID 39722219 Get It

Esophageal squamous cell carcinoma (ESCC) remains a significant global health challenge, being the sixth leading cause of cancer mortality with pronounced geographic variability. The incidence rates range from 125 per 100,000 in northern China to 1–1.5 per 100,000 in the United States, driven by environmental and lifestyle factors such as tobacco and alcohol use, dietary habits, and pollution. Major modifiable risk factors include tobacco and alcohol consumption, with a synergistic risk increase when combined. Nonmodifiable risk factors include previous diagnoses of head and neck squamous cell carcinoma (H&N SCC), achalasia, and prior radiotherapy. Prevention strategies must be tailored to specific regional burdens to efficiently allocate medical and financial resources. Gastrointestinal endoscopy is crucial in reducing ESCC burden through early detection and characterization of neoplastic changes, such as high‐grade dysplasia. Early diagnosis significantly improves survival rates, while endoscopic resection of noninvasive dysplasia can prevent ESCC onset, reducing treatment burden for advanced disease. Postresection surveillance can detect high‐risk metachronous lesions. Despite these benefits, endoscopic prevention faces challenges, including the lack of high‐level evidence supporting its efficacy, opportunity costs, the need for specialized training and techniques, and the requirement for advanced technology investments. This Position Statement from the World Endoscopy Organization (WEO) aims to address these challenges, supplying recommendations for the exploitation of endoscopic resources regarding the possible role of screening, quality, and training for the detection, characterization, resection, and surveillance of ESCC.
Expert consensus recommendations on dermoscopy proficiency standards for physician assistants: results of a modified Delphi survey
Young, Peter A. , Middleton, Hayden T. , Froiland, Christi, Keeter, Nicole, Sanders, Kim B., DiRuggiero, Douglas , Pettey, Adam A., Swanson, David C. , Marghoob, Ashfaq A. , McCleskey, Patrick E. , Seiverling, Elizabeth V. , Griffith, Cynthia Faires , Sanders, Kim B., Bae, Gordon Hyeonjin , Mostaghimi, Arash , Nelson, Kelly C.

Mayo Clinic

Journal of Dermatology for Physician Assistants | December 25, 2024 | Volume: 19 | Issue: 1 | Pages: 14-19

10.1097/jdpa.0000000000000047 Get It

Importance: Dermoscopy is increasingly recognized by skin cancer experts and professional leaders as an essential skill for physicians in dermatology and primary care. A substantial number of patients in both settings also receive care from physician assistants (PAs), who provide additional opportunities to evaluate patients with concerning skin lesions. Earning dermatology-specific credentials from the National Commission on Certification for PAs requires passing a written exam with dermoscopic content, and 77% of practicing PAs (all specialties) believe dermoscopy should be a standard element of their formal education. No published studies have identified precise learning objectives that would represent appropriate foundational proficiency in dermoscopy for PAs. Objective: We sought to identify common diagnoses with distinct dermoscopic features and delineate which of these represent appropriate proficiency expectations for early-career PAs in primary care and dermatology. Design, setting, and participants: A panel of 14 dermoscopists was assembled (8 dermatologists; 6 PAs), reflecting contributors to existing consensus statements on physician dermoscopy proficiency benchmarks, dermatologist-recommended competencies for PAs, and/or standardized test content for dermatology PAs. Panelists completed a modified Delphi consensus process involving electronic surveys and roundtable discussions. Main outcomes and measures: Consensus on which specific dermoscopic diagnoses reflect appropriate foundational proficiency expectations for PAs in both primary care and dermatology. Results: Twelve of 14 panelists (86%) reported using dermoscopy for over 12 years (mean: 15.5 y). All panelists completed 2 iterations of an electronic survey regarding 54 diagnoses, with 39 (72%) reaching a final consensus for inclusion in PA curricula and 15 (28%) being identified as non-priority items for early-career PAs. Panelists recommended 14 conditions for primary care PAs and 25 conditions for dermatology PAs. Conclusions and Relevance: Consensus achieved in this modified Delphi process identified diagnoses that represent pragmatic learning objectives to achieve foundational proficiency in dermoscopy for PAs in both primary care and dermatology. This list of validated objectives provides a consensus-based guide to help educators, supervising physicians, and professional leaders to cultivate specialty-appropriate dermoscopic proficiency among early-career PAs.
Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration
Sandahl, Tyler B. , Soefje, Scott A. , Ailawadhi, Sikander , Parrondo, Ricardo , Lin, Dee , Wu, Bingcao , Calay, Ediz S. , Silvert, Eli , Carpenter, Corinne , Wagner, Tyler E. , Fowler, Jessica , Hester, Laura , Rangarajan, Nivedita , Marshall, Alexander Mclean, Stoy, Patrick, Gifkins, Dina , Kumar, Shaji , Ailawadhi, Sikander , Parrondo, Ricardo D , Lin, Dee , Wu, Bingcao , Calay, Ediz S , Wagner, Tyler E , Hester, Laura , Murugadoss, Karthik , Gifkins, Dina , Lin, Yi , Kumar, Shaji K , Soefje, Scott A , Sandahl, Tyler B , Fonseca, Rafaël , Kim, Nina , Fowler, Jessica, Murugadoss, Karthik , Marshall, Alexander, Lin, Yi

Mayo Clinic

JCO Oncology Practice | December 20, 2024 | Volume: 21 | Issue: 5 | Pages: 702-709

10.1200/op-24-00489 | PMID 39705632 Get It

PURPOSE Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital setting. This study aimed to evaluate safety and health care resource utilization (HRU) in real-world patients with multiple myeloma who initiated teclistamab SUD in an outpatient setting. METHODS This was a retrospective study using Mayo Clinic's electronic medical records from October 26, 2022, to October 31, 2023. Patient characteristics were summarized for all patients treated with teclistamab and separately for patients who started SUD outpatient. SUD pattern, safety, HRU, and post-SUD dosing schedule were described in patients with complete SUD. RESULTS At data cutoff, 65 patients received ≥1 teclistamab dose, including 58 patients who initiated SUD outpatient (median age, 69.2 years; male, 63.8%; White, 89.7%). Among 57 patients who completed SUD in an outpatient setting, all received premedications on the days of teclistamab administrations per label recommendation; 18 (31.6%) developed CRS (13 grade 1, four grade 2, and one grade 4) and two developed ICANS (one each with grade 2 and 4). All CRS and ICANS resolved with supportive care and all patients continued treatment. Eighteen patients were admitted to the hospital for CRS treatment, with a median CRS-related hospital stay of 2 days per admission. Most (60%) doses during SUD required <1 hour clinic time between administration and checkout. Post-SUD, clinic time for treatment doses decreased to <30 minutes for most doses (82%). CONCLUSION Outcomes of this study support outpatient administration as a safe and feasible option for teclistamab SUD to potentially reduce HRU and improve patient experiences.
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
Morris, Van K. , Kennedy, Erin B. , Amin, Manik , Aranha, Olivia , Benson, Al B. , Dorth, Jennifer A. , Horowitz, David P. , Kennecke, Hagen F. , Kim, Stéfano , Kreppel, Lillian, Rajdev, Lakshmi , Mettu, Niharika B , Riechelmann, Rachel , Sio, Terence T , Eng, Cathy , Riechelmann, Rachel P. , Sio, Terence T. , Eng, Cathy

Mayo Clinic

Journal of Clinical Oncology | December 16, 2024 | Volume: 43 | Issue: 5 | Pages: 605-615

10.1200/jco-24-02120 | PMID 39680825 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgement. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard-of-care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only). PURPOSE To provide evidence-based guidance for clinicians who treat patients with stage I-III anal cancer. METHODS A systematic review of the literature conducted by the Minnesota Evidence-based Practice Center provided the evidence base for this guideline. An ASCO Expert Panel reviewed this evidence and came to consensus on a set of evidence-based recommendations. RESULTS The systematic review contained three randomized controlled trials and three nonrandomized studies of interventions that were relevant to the guideline topic and informed the recommendations. RECOMMENDATIONS Mitomycin-C (MMC) with a fluoropyrimidine (fluorouracil [FU] or capecitabine) is recommended as the radiosensitizing component of chemoradiation (CRT) for anal cancer; the Expert Panel recognizes that capecitabine is often used as an orally administered alternative to FU and is currently being used in ongoing clinical trials. Cisplatin with FU is an additional chemotherapy combination that may be recommended as radiosensitizing chemotherapy. Because of the myelosuppression associated with MMC, the preferable regimen for patients with immunosuppression is cisplatin and FU. Cisplatin is not recommended for patients with renal dysfunction, significant neuropathy, or hearing loss, and there is no evidence to recommend substituting carboplatin for cisplatin. Dose and schedule options for recommended chemotherapy agents are included within the full text of the guideline. Routine induction chemotherapy before CRT and additional chemotherapy after CRT are not recommended for patients with localized anal cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Contribution of rare chromosome 22q11.2 copy number variants to non-syndromic bicuspid aortic valve
DiGregorio, Helene , Mansoorshahi, Sara , Carlisle, Steven Grant , Pensa, Catherina Tovar, Watts, Abi, McNeely, Courtney, Sabaté-Rotés, Anna , Yetman, Anji T. , Michelena, Héctor I. , Backer, Julie De , Bissell, Malenka M. , Hui, Dawn S. , Caffarelli, Anthony, Marco, Margot De , Tretter, Justin T. , Body, Simon C. , Morris, Shaine A. , De Backer, Julie F A , Kim, Yuli Y , Citro, Rodolfo , Tretter, Justin T , Prakash, Siddharth K , Morris, Shaine A , Michelena, Hector I , Bissell, Malenka M , Carlisle, Steven G, Pensa, Catherina Tovar, Mosquera, Laura Muiño , Andreassi, Maria Grazia , Foffa, Ilenia , Kim, Yuli Y. , Citro, Rodolfo , McBride, Kim L. , Milewicz, Dianna M. , Prakash, Siddharth K.

Mayo Clinic

Heart | December 10, 2024 | Volume: 111 | Issue: 5 | Pages: 221-229

10.1136/heartjnl-2024-324669 | PMID 39658198 Get It

Background Bicuspid aortic valve (BAV) is the most common congenital heart defect in adults, often leading to complications such as thoracic aortic aneurysms and aortic stenosis. While BAV is frequently associated with 22q11.2 deletion syndrome (22q11.2DS), the contribution of rare copy number variants (CNVs) in this region to non-syndromic BAV is less clear. This study is aimed to assess the role of rare 22q11.2 CNVs in patients with early-onset BAV (EBAV) and to determine whether these variants are linked to an increased risk of complications. Methods Whole genome microarray genotyping was conducted on 272 patients with BAV with early onset valve or aortic disease (EBAV) and 272 biological relatives. CNVs were detected using three independent algorithms, focusing on the 22q11.2 region (18–24 Mb). CNV burden in the EBAV cohort was compared with unselected European ancestry controls. Results Rare duplications and deletions within the 22q11.2 region, particularly involving genes associated with cardiac development, were identified in 7.4% of EBAV probands. These CNVs were significantly enriched compared with the general population and segregated with BAV in families. Individuals carrying rare 22q11.2 CNVs had a higher prevalence of psychiatric diagnoses and learning difficulties, although they did not exhibit the typical features of 22q11.2DS. Importantly, these CNVs were associated with early onset or complex BAV cases, underscoring their potential clinical relevance. Conclusions Rare 22q11.2 CNVs play a role in non-syndromic BAV, particularly in cases with early onset or complex presentations. CNV screening could be considered as part of risk stratification for patients with BAV, helping to predict complications and guide management. Trial registration number NCT01823432 .
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
Guan, Li , Torres‐Saavedra, Pedro A. , Zhao, Xiaobei , Major, Michael B. , Holmes, Brittany , Nguyen, Ngan K. , Kumaravelu, Parasakthy , Hodge, Tim , Diehn, Maximilian , Zevallos, Jose P. , Emami, Bahman, Hayward, Michele C. , Sagar, Stephen M. , Morrison, William H. , Schultz, Christopher J. , Jones, Christopher U. , Galloway, Thomas J. , Yom, Sue S. , Kudrimoti, Mahesh , Kim, Harold E., Harris, Jonathan , Le, Quynh‐Thu , Holmes, Brittany J , Zevallos, Jose , Holsinger, F Chris , Emami, Bahman , Jordan, Richard C , Hayward, Michele C , Sagar, Stephen M , Morrison, William , Schultz, Christopher , Caudell, Jimmy J , Jones, Christopher U , Bratman, Scott V , Galloway, Thomas J , Ma, Daniel , Yom, Sue S , Kudrimoti, Mahesh , Kim, Harold E , Harris, Jonathan , Le, Quynh-Thu , Hayes, D Neil , Diehn, Maximillian , Holsinger, F. Christopher , Daniel, J.

Mayo Clinic

Clinical Cancer Research | December 10, 2024 | Volume: 31 | Issue: 9 | Pages: 1615-1624

10.1158/1078-0432.ccr-24-2334 | PMID 39656603 Get It

Abstract Purpose: NFE2L2/KEAP1/CUL3 mutations have been validated for radioresistance in cell-based assays and animal models. However, clinical validation of these biomarkers has been challenging because of multimodality treatment regimens. This study aims to investigate the association between NFE2L2/KEAP1/CUL3 mutations and patient outcomes, including local failure, locoregional failure, disease-free survival (DFS), and overall survival, using samples from a phase III trial in which patients were treated with radiation monotherapy at two controlled doses. Patients and Methods: We investigated NFE2L2/KEAP1/CUL3 mutations in 250 randomized patients with T2N0 glottic squamous cell carcinoma receiving definitive radiotherapy in the NRG/RTOG 9512 trial. A total of 119 patients had available biospecimens that were subjected to amplicon-based next-generation sequencing to assess for the presence of NFE2L2/KEAP1/CUL3 mutations without regard to outcomes. Mutations in NFE2L2/KEAP1/CUL3 were assessed blinded to clinical outcomes. Cox models (two-sided α = 0.05) were used to evaluate the association with clinical outcomes, performed by an independent statistical team. Results: Nineteen of 119 patients (16.0%) had NFE2L2/KEAP1/CUL3 mutations. Patient, treatment, and tumor characteristics were similar between those with and without mutations. Patients with mutation compared with those without had significantly more local failure [HR = 3.50; 95% confidence interval (CI), 1.56–7.89; P = 0.0025] and locoregional failure (HR = 3.80; 95% CI, 1.80–8.03; P = 0.0005). DFS was significantly worse for the mutated compared with the nonmutated group in the first 2 years (HR = 2.88; 95% CI, 1.46–5.66; P = 0.0022). The median DFS was shorter in the mutation group (10.3 months) versus those with intact NFE2L2/KEAP1/CUL3 (4.2 years). Conclusions: NFE2L2/KEAP1/CUL3 mutations may predict radiation treatment failure in T2N0 glottic cancer. See related commentary by Rao, p. 1563
Asthma Among Children With Primary Ciliary Dyskinesia
Zein, Joe , Kim, Hyun Jo , Marozkina, Nadzeya , Gaston, Benjamin , Owora, Arthur Hamie , Marozkina, Nadzeya

Mayo Clinic

JAMA Network Open | December 9, 2024 | Volume: 7 | Issue: 12 | Pages: e2449795

10.1001/jamanetworkopen.2024.49795 | PMID 39652350 Get It

This case-control study uses electronic health record data to assess the association between primary ciliary dyskinesia and asthma in children.
S5 Sustained Improvements in Health-Related Quality of Life Outcomes With Long-Term Risankizumab Treatment in Patients With Moderately to Severely Active Crohn’s Disease: Results from the FORTIFY Open-Label, Long-Term Extension
Joshi, Namita , Griffith, Jenny, Song, Alexandra , Kim, Brooke, Platt, Andrew M. , Louis, Édouard , Loftus, Edward V. , Peyrin‐Biroulet, Laurent , Ghosh, Subrata , Shukla, Nidhi , Louis, Edouard

Mayo Clinic

American Journal of Gastroenterology | December 9, 2024 | Volume: 119 | Issue: 12S | Pages: S2-S2

10.14309/01.ajg.0001082552.29774.dc Get It

Classical Ozaki Procedure in a Seven-Month-Old Infant
Черногривов, А.Е. , Kim, A.I. , Cetta, Frank , Rogova, Tatyana V. , Нефедова, И.Е. , Черногривов, И.Е. , Esayan, Ashot, Донцова, В.И. , Sarkisyan, Alina S., Chernogrivov, Aleksei Ye

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | December 9, 2024 | Volume: 16 | Issue: 3 | Pages: 413-416

10.1177/21501351241297712 | PMID 39648496 Get It

We present a case study of neotricuspidization of the aortic valve with neocusp suturing based on templates similar to those used in the Ozaki procedure but adapted for infants. This is an alternative for patients when valve reconstruction is impossible or risky. A good postoperative hemodynamic outcome was obtained, but it is necessary to evaluate this approach on the basis of long-term results.